Quality of life and mood assessment in conservatively treated cavernous malformation-related epilepsy.
anxiety
cerebral cavernous malformation
depression
epilepsy
quality of life
Journal
Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
03
03
2022
received:
10
01
2022
accepted:
04
04
2022
pubmed:
27
4
2022
medline:
28
6
2022
entrez:
26
4
2022
Statut:
ppublish
Résumé
To estimate the quality of life, anxiety, depression, and illness perception in patients with medically treated cerebral cavernous malformation (CCM) and associated epilepsy. Nonsurgically treated patients with CCM-related epilepsy (CRE) were included. Demographic, radiographic, and clinical features were assessed. All participants received established questionnaires (short-form 36 health survey, SF-36; hospital anxiety and depression score, HADS-A/D; visual analogue scale score, VAS) assessing the functional and psychosocial burden of disease. To some extent, calculated values were compared with reference values from population-based studies. Test results were related to seizure control. A total of 37 patients were included. Mean age was 45.8 ± 14.4 years, and 54.1% were female. Diagnosis of CRE was significantly associated with attenuated quality of life and increased level of anxiety, affecting physical and psychosocial dimensions. The assessment of illness perception identified considerable burden. HADS was significantly associated with VAS and SF-36 component scores. Efficacy of antiepileptic medication had no restoring impact on quality of life, anxiety, depression, or illness perception. CRE negatively influences quality of life and mood, independent of seizure control due to antiepileptic medication. Screening for functional and psychosocial deficits in clinical practice might be useful for assessing individual burden and allocating surgical or drug treatment.
Sections du résumé
BACKGROUND
To estimate the quality of life, anxiety, depression, and illness perception in patients with medically treated cerebral cavernous malformation (CCM) and associated epilepsy.
METHODS
Nonsurgically treated patients with CCM-related epilepsy (CRE) were included. Demographic, radiographic, and clinical features were assessed. All participants received established questionnaires (short-form 36 health survey, SF-36; hospital anxiety and depression score, HADS-A/D; visual analogue scale score, VAS) assessing the functional and psychosocial burden of disease. To some extent, calculated values were compared with reference values from population-based studies. Test results were related to seizure control.
RESULTS
A total of 37 patients were included. Mean age was 45.8 ± 14.4 years, and 54.1% were female. Diagnosis of CRE was significantly associated with attenuated quality of life and increased level of anxiety, affecting physical and psychosocial dimensions. The assessment of illness perception identified considerable burden. HADS was significantly associated with VAS and SF-36 component scores. Efficacy of antiepileptic medication had no restoring impact on quality of life, anxiety, depression, or illness perception.
CONCLUSIONS
CRE negatively influences quality of life and mood, independent of seizure control due to antiepileptic medication. Screening for functional and psychosocial deficits in clinical practice might be useful for assessing individual burden and allocating surgical or drug treatment.
Identifiants
pubmed: 35470577
doi: 10.1002/brb3.2595
pmc: PMC9226805
doi:
Substances chimiques
Anticonvulsants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2595Informations de copyright
© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
Références
Lancet Neurol. 2016 Feb;15(2):166-173
pubmed: 26654287
J Neurosurg. 2017 Apr;126(4):1303-1311
pubmed: 27367244
Epilepsia. 2019 Feb;60(2):220-232
pubmed: 30653657
Neurosurg Focus. 2020 Apr 1;48(4):E6
pubmed: 32234980
Seizure. 2017 Feb;45:64-69
pubmed: 27936450
Neurology. 2014 Aug 12;83(7):582-9
pubmed: 24994841
Turk Neurosurg. 2022;32(3):386-391
pubmed: 34664700
Neurology. 2016 May 24;86(21):1984-91
pubmed: 27164680
Seizure. 2019 Jul;69:31-40
pubmed: 30959423
Neurosurgery. 2010 Oct;67(4):918-24
pubmed: 20881556
Neurosurg Focus. 2010 Sep;29(3):E16
pubmed: 20809757
Eur J Neurol. 2021 Feb;28(2):491-499
pubmed: 32961598
Med Care. 1995 Apr;33(4 Suppl):AS264-79
pubmed: 7723455
J Psychosom Res. 2011 Aug;71(2):74-8
pubmed: 21767686
Lancet Neurol. 2012 Mar;11(3):217-24
pubmed: 22297119
Neurosurg Focus. 2010 Sep;29(3):E7
pubmed: 20809765
Am Heart J. 2002 Aug;144(2):212-8
pubmed: 12177636
Epilepsia. 2013 Dec;54(12):2025-35
pubmed: 24134485
Neuropediatrics. 2018 Jun;49(3):173-179
pubmed: 29677701
Stroke. 2008 Dec;39(12):3222-30
pubmed: 18974380
Int J Stroke. 2019 Dec;14(9):939-945
pubmed: 31122172
Epilepsy Behav. 2021 Feb;115:107662
pubmed: 33339740
Med Care. 1995 Jan;33(1):15-28
pubmed: 7823644
J Neurosurg. 2021 Oct 1;:1-11
pubmed: 34598135
J Neurosurg. 2019 Jul 1;131(1):1-13
pubmed: 31261134
PLoS One. 2015 Aug 25;10(8):e0136619
pubmed: 26305879
World Neurosurg. 2016 Nov;95:315-321
pubmed: 27542564
Lancet Neurol. 2016 Apr;15(4):354-5
pubmed: 26831334
Brain Behav. 2022 Jun;12(6):e2595
pubmed: 35470577
Neurosurg Focus. 2020 Apr 1;48(4):E12
pubmed: 32234994
World Neurosurg. 2017 Dec;108:869-875
pubmed: 28844916
Neurologia. 2013 May;28(4):195-204
pubmed: 22743210
Neurosurgery. 2011 Sep;69(3):689-95
pubmed: 21508880
Cerebrovasc Dis. 2017;44(5-6):313-319
pubmed: 28968597
Neurosurg Rev. 2017 Jan;40(1):39-43
pubmed: 27822594
Law Hum Behav. 2005 Oct;29(5):615-20
pubmed: 16254746
Seizure. 2013 Mar;22(2):128-35
pubmed: 23273809